Sattva Neelapu

Sattva Neelapu at MD Anderson was the principal investigator of ZUMA-1 — the pivotal trial establishing axicabtagene ciloleucel (axi-cel, anti-CD19 CAR-T) for relapsed/refractory large B-cell lymphoma. He also led ZUMA-7 demonstrating axi-cel superiority over standard salvage/transplant as second-line therapy for DLBCL — a paradigm-shifting finding that moved CAR-T to earlier in the treatment sequence. His work has been foundational for CD19 CAR-T therapy in B-cell lymphomas.